Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.

JSON

Tobiasson M, Pandzic T, Cavelier L, Sander B, Wahlin BE

Leuk. Lymphoma 60 (13) 3316-3319 [2019-12-00; online 2019-06-17]

Clinical Genomics Uppsala [Collaborative]

PubMed 31204875

DOI 10.1080/10428194.2019.1627541

Crossref 10.1080/10428194.2019.1627541